NCT05591053 2024-02-21
Utility and Usability of ActivSightâ„¢ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans
Activ Surgical
Phase NA Unknown
Clinical Trials
128 trialsNCT04844385 2024-02-09
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT02465736 2024-01-16
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
Sun Yat-sen University
Phase 3 Unknown
NCT05626569 2024-01-03
Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC
Sun Yat-sen University
Phase 2 Unknown
NCT05512520 2023-11-18
EC-CRT-003
Sun Yat-sen University
Phase 2 Unknown
NCT06078657 2023-10-12
IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05990231 2023-09-11
Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT03790553 2023-08-03
Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma
Fudan University
Phase 3 Unknown
NCT05927844 2023-07-03
XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 1 Unknown
NCT05603065 2023-06-29
TINES
First Affiliated Hospital Xi'an Jiaotong University
Phase 4 Unknown
NCT05900583 2023-06-12
Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.
Guangdong Provincial People's Hospital
Unknown
NCT05038813 2023-05-18
Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT03958890 2023-04-18
A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Shanghai Henlius Biotech
Phase 3 Unknown
NCT05163483 2023-03-06
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT02025036 2023-02-08
CRTCOESC
The First Affiliated Hospital of Henan University of Science and Technology
Phase 3 Unknown
NCT04425122 2023-02-08
The Microbiome of Oesophageal Squamous Cell Carcinoma
Chinese University of Hong Kong
Unknown
NCT05650216 2022-12-14
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
Shanghai Chest Hospital
Phase 2 Unknown
NCT05636150 2022-12-05
A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05633641 2022-12-02
Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma
Fudan University
Unknown
NCT05386056 2022-11-28
Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Unknown
NCT05596890 2022-11-28
PICCRT
Guangdong Provincial People's Hospital
Phase 2 Unknown
NCT05594914 2022-10-26
AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of University of South China
Phase 2 Unknown
NCT05561699 2022-09-30
SPEED
Shanghai Zhongshan Hospital
Phase NA Unknown
NCT05552651 2022-09-23
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Air Force Military Medical University, China
Phase 2 Unknown
NCT05541445 2022-09-15
Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Unknown
NCT05522894 2022-08-31
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
ChineseAMS
Phase 2 Unknown
NCT04699994 2022-08-17
Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel
Keio University
Phase 2 Unknown
NCT05170256 2022-08-12
HERES
Rigshospitalet, Denmark
Phase 2 Unknown
NCT05469061 2022-07-21
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05426850 2022-06-22
ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma
Fudan University
Unknown
NCT05213312 2022-06-15
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
Shanghai Zhongshan Hospital
Phase 2/3 Unknown
NCT04215471 2022-06-14
NATION1907II
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03623737 2022-06-07
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
National Taiwan University Hospital
Phase 2/3 Unknown
NCT05394415 2022-05-27
LATE
Jiangsu Cancer Institute & Hospital
Phase 1/2 Unknown
NCT05322499 2022-04-11
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05317325 2022-04-07
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
Sichuan University
Phase 1 Unknown
NCT05287880 2022-03-18
Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC
Fifth Affiliated Hospital, Sun Yat-Sen University
Unknown
NCT04390958 2022-03-15
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
ChineseAMS
Phase 2 Unknown
NCT05265962 2022-03-04
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04177797 2022-02-09
Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT05199649 2022-01-20
Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT05174325 2021-12-30
Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05007145 2021-12-21
REVO
Fujian Cancer Hospital
Phase 2 Unknown
NCT04506138 2021-12-14
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 1/2 Unknown
NCT02915432 2021-12-13
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT05044728 2021-09-16
Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT03800953 2021-09-08
The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
Phase 2 Unknown
NCT03387904 2021-09-02
Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05028231 2021-08-31
NICCE
Tongji Hospital
Unknown
NCT04514835 2021-08-25
A Phase â…¡ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown